-
2022-10-28
专访优锐医药：呼吸精品特药领域，如何打造现金“造血”教科书？
近日，动脉新医药访谈了优锐医药创始人兼CEO Mark Lotter先生。Mark Lotter曾是阿斯利康的首批来华高管，拥有超过20年的中国医疗行业市场经验。Mark Lotter与我们分享了优锐医药如何练就现金“造血”能力，并逐步成长为具有差异化的特药医疗公司。
-
2022-10-14
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces additional exacerbation* subgroup analyses from the Phase 3 ENHANCE-2 (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) trial in chronic obstructive pulmonary disease
-
2022-09-07
优锐医药助力2022第十一届中国罕见病高峰论坛成功举办
2022年9月2日，第十一届中国罕见病高峰论坛于上海隆重开幕。本届大会以“初心如一 一路同行”为主题，作为国内历史最久，规模最大，影响力最为深远的中国罕见病领域综合性论坛
-
2022-08-18
IND Approval for Ensifentrine Pivotal Clinical Trials for COPD in China
Nuance Pharma announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial of Ens
-
2022-08-09
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces its top-line Phase 3 ENHANCE-2 ("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") trial results evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary d
-
2022-07-26
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
Nuance Pharma announces the completion of dosing for all HNVs in the Phase I clinical study of its novel Ketorolac for IV infusion (NTM-001), a non-opioid analgesic drug co-developed with N
-
2022-07-13
Nuance Pharma advances Rare Disease R&D with CORD
July 11th, 2022, Mr. Mark Lotter, founder and CEO of Nuance Pharma, visited Chinese Organization for Rare Disorders (CORD) and met with Mr. Huang Rufang, founder and president of CORD.
-
2022-06-27
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs
Contact PR
